Back to Search Start Over

Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients

Authors :
Yvon Berland
Stanislas Bataille
M. Pelletier
A. Duval
Marion Sallée
Stéphane Burtey
Nathalie McKay
Yosra Mouelhi
Stéphanie Gentile
Philippe Brunet
Centre de néphrologie et transplantation rénale [Hôpital de la Conception - APHM]
Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION)
Vascular research center of Marseille (VRCM)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)
Université Bordeaux Segalen - Bordeaux 2
Hôpital de la Conception [CHU - APHM] (LA CONCEPTION)
Hôpital de la Conception [CHU - APHM] (LA CONCEPTION)-Assistance Publique - Hôpitaux de Marseille (APHM)
Source :
BMC Nephrology, Vol 18, Iss 1, Pp 1-9 (2017), BMC Nephrology, BMC Nephrology, BioMed Central, 2017, 18 (1), pp.251. ⟨10.1186/s12882-017-0668-5⟩
Publication Year :
2017
Publisher :
BMC, 2017.

Abstract

Background The main reason for anemia in renal failure patients is the insufficient erythropoietin production by the kidneys. Beside erythropoietin deficiency, in vitro studies have incriminated uremic toxins in the pathophysiology of anemia but clinical data are sparse. In order to assess if indole 3-acetic acid (IAA), indoxyl sulfate (IS), and paracresyl sulfate (PCS) -three protein bound uremic toxins- are clinically implicated in end-stage renal disease anemia we studied the correlation between IAA, IS and PCS plasmatic concentrations with hemoglobin and Erythropoietin Stimulating Agents (ESA) use in hemodialysis patients. Methods Between June and July 2014, we conducted an observational cross sectional study in two hemodialysis center. Three statistical approaches were conducted. First, we compared patients treated with ESA and those not treated. Second, we performed linear regression models between IAA, IS, and PCS plasma concentrations and hemoglobin, the ESA dose over hemoglobin ratio (ESA/Hemoglobin) or the ESA resistance index (ERI). Third, we used a polytomous logistic regression model to compare groups of patients with no/low/high ESA dose and low/high hemoglobin statuses. Results Overall, 240 patients were included in the study. Mean age ± SD was 67.6 ± 16.0 years, 55.4% were men and 42.5% had diabetes mellitus. When compared with ESA treated patients, patients with no ESA had higher hemoglobin (mean 11.4 ± 1.1 versus 10.6 ± 1.2 g/dL; p 20%) linear regression between IAA, IS or PCS and any anemia parameter did not reach significance. In the third model, univariate analysis showed no intergroup significant differences for IAA and IS. Regarding PCS, the Low Hb/High ESA group had lower concentrations. However, when we compared PCS with the other significant characteristics of the five groups to the Low Hb/high ESA (our reference group), the polytomous logistic regression model didn’t show any significant difference for PCS. Conclusions In our study, using three different statistical models, we were unable to show any correlation between IAA, IS and PCS plasmatic concentrations and any anemia parameter in hemodialysis patients. Indolic uremic toxins and PCS have no or a very low effect on anemia parameters.

Details

Language :
English
ISSN :
14712369
Volume :
18
Issue :
1
Database :
OpenAIRE
Journal :
BMC Nephrology
Accession number :
edsair.doi.dedup.....4e54c74c515211eedb2ef9cd8f71e0e8
Full Text :
https://doi.org/10.1186/s12882-017-0668-5